More on Teva (TEVA) Q3: swings to net loss of $79M from profit of $916M last year, due to $670M provision connected to patent litigation and $481M impairment mostly related to R&D. U.S. sales +33% to $2.6B, boosted by the acquisition of Cephalon. Europe sales +13% in local currencies. Copaxone revenue +13% to $1.05B. Narrows 2012 guidance range to $5.32-$5.38 for EPS and $20.1B-$20.7B for revenue, both in line.